WCP
REGN icon

Wick Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Wick Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-606
Closed -$468K – 281
2026
Q1 		$468K Buy
606
+171
+39% +$131K 0.09% 102
2025
Q4 		$336K Buy
+435
New +$295K 0.06% 132

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Wick Capital Partners's REGN Position: Q2 2026 in Review

Wick Capital Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 606 shares — an estimated $468K sold.

Wick Capital Partners first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $468K in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Wick Capital Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Wick Capital Partners sold 606 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $468K.
  • Wick Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Wick Capital Partners's Regeneron Pharmaceuticals position peaked at $468K in Q1 2026.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Wick Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.